Radioimmunoassay of zidovudine: Extended use and potential application

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 195-200

  DeRemer, Mary ^a   D'Ambrosio, Robin ^a   Bartos, Linda ^a   Cousins, Stephen ^a   Morse, Gene D ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Radioimmunoassay; Zidovudine

Indexed keywords

ZIDOVUDINE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MONITORING; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RADIOIMMUNOASSAY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; RADIOIMMUNOASSAY; ZIDOVUDINE;

EID: 0031441323     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00014     Document Type: Article

References (33)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990;112: 727-37.
3. + cells/mm3. Initial results of Protocol 019, a trial of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Disease. N Engl J Med 1994;322:941-9.
4. Good SS, Reynolds DJ, DeMiranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr 1988;431: 123-33.
5. Granich GG, Eveland MR, Krogstad DJ. Fluorescence polarization immunoassay for zidovudine. Antimicrob Agent Chemother 1989;33:1275-9.
6. Pivarnik PE, Horton C, Kim R, Davis IM, Dudley MN. Performance of a rapid, sensitive fluorescence polarization immunoassay for measurement of zidovudine and its glucuronide metabolite in serum and urine. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 1994.
7. ZDV-Trak Product Information. INCStar, Inc., 1994.
8. Linnet K. Estimation of the linear relationship between the measurements of two methods with proportional errors. Stat Med 1990;9:1463-73.
9. Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem 1993;39:424-32.
10. Cordaro JA, Morse GD, Bartos L, et al. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cvcle. Pharmacotherapy 1993;13:369-77.
11. Drusano GL, Balis FM, Gitterman SR, Pizzo PA. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994;38:1726-31.
12. Stretcher BN, Pesce AJ, Hurtubise PE, Frame PT. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monit 1991;14:281-5.
13. Fletcher CV, Rhame FS, Beatty CC, Simpson M, Balfour HH Jr. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992;12:429-34.
14. Gitterman SR, Drusano GL, Egorin MJ, Standiford HC, The Veterans Administration Cooperative Studies Group. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990;48:161-7.
15. Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1990;34:394-7.
16. Tartaglione TA, Collier AC, Opheim K, Gianola FG, Benedetti J, Corey L. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2225-31.
17. Acosta EP, Henry K, Erice A, Page LM, Balfour HH Jr, Fletcher CV. Concentration-controlled zidovudine therapy: rationale and methods. Second National Conference on Human Retroviruses and Related Infections, Washington, DC, 1995.
18. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
19. Blum MR, Liao SHT, Good SS, DeMiranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85(2a):189-194.
20. Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins RF. Plasma and CSF pharmacokinetics of 3′-azido-3′-deoxythymidine. Clin Pharmacol Ther 1987;41:407-12.
21. Morse GD, Portmore AC, Marder V, et al. Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agent Chemother 1992;36:2245-52.
22. Shelton MJ, Morse GD, Portmore A, Blum MR, Sadler BM, Reichman RC. Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapeutics 1994;14(6):671-7.
23. Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet 1989;2:473-5.
24. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agent Chemother 1993;37:1426-31.
25. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
26. O'Donnell AM, Letting DJ, DeRemer MF, Morse GD. Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay. Antimicrob Agent Chemother 1994;38: 2689-94.
27. Stretcher BN, Pesce AJ, Geisler BA, Vine WH. A coupled HPLC/radioimmunoassay for analysis of zidovudine metabolites in mononuclear cells. J Liquid Chromatogr 1991;14: 2261-72.
28. Slusher JT, Kuwahara SK, Hamazeh FM, Lewis LD, Kornhauser DM, Lietman PS. Intracellular zidovudine and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992;36:2473-7.
29. Stretcher BN, Pesce AJ, Murray JA, Hurtubise PE, Vine WH, Frame PT. Concentrations of phosphorylated zidovudine in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit 1991;13:325-31.
30. Stretcher BN, Pesce AJ, Wermeling JR, Hurtubise PE. In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes. Ther Drug Monit 1990;12:481-9.
31. Kuster H, Vogt M, Joos B, Nadai V, Luthy R. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991;164:773-6.
32. Chiang H, Shelton M, Hewitt R, Grasela T, Morse GD. Zidovudine pharmacodynamics in HIV infected patients. 1993 Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans.
33. Shah VP, Midha KK, Digne S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.